R C Tarazi, H P Dustan. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Administration, OralAntihypertensive Agents/therapeutic useBlood Pressure/drug effectsCardiac Output/drug effectsDrug SynergismFollow-Up StudiesHeart Rate/drug effectsHemodynamics/drug effectsHumansHypertension/drug therapyInjections, IntravenousPropranolol/administration & dosagePropranolol/adverse effectsPropranolol/pharmacologyPropranolol/therapeutic usePyridazines/therapeutic useSympatholytics/therapeutic useTime Factors
Substances: See more » Antihypertensive AgentsPyridazinesSympatholyticsPropranolol
Year: 1972 PMID: 5021493 DOI: 10.1016/0002-9149(72)90164-6
Source DB: PubMed Journal: Am J Cardiol ISSN: 0002-9149 Impact factor: 2.778